Lower urinary tract symptoms in men
暂无分享,去创建一个
[1] P. Abrams,et al. Lower urinary tract symptom: still too much focus on the prostate? , 2014, Current opinion in urology.
[2] S. Maclennan,et al. Systematic review and meta‐analysis of the clinical effectiveness of bipolar compared with monopolar transurethral resection of the prostate (TURP) , 2014, BJU international.
[3] John T. Wei,et al. The efficacy and safety of combined therapy with α-blockers and anticholinergics for men with benign prostatic hyperplasia: a meta-analysis. , 2013, The Journal of urology.
[4] J. Macoska,et al. Promising Molecular Targets and Biomarkers for Male BPH and LUTS , 2013, Current Urology Reports.
[5] C. Roehrborn,et al. Systematic review of combination drug therapy for non-neurogenic male lower urinary tract symptoms. , 2013, European urology.
[6] J. Mckinlay,et al. Intake of caffeinated, carbonated, or citrus beverage types and development of lower urinary tract symptoms in men and women. , 2013, American journal of epidemiology.
[7] H. Woo,et al. Photoselective vaporization with the green light laser vs transurethral resection of the prostate for treating benign prostate hyperplasia: a systematic review and meta‐analysis , 2013, BJU international.
[8] M. Marberger,et al. A randomized double-blind placebo-controlled phase 2 dose-ranging study of onabotulinumtoxinA in men with benign prostatic hyperplasia. , 2013, European urology.
[9] T. Morita,et al. Investigation of ejaculatory disorder by silodosin in the treatment of prostatic hyperplasia , 2012, BMC Urology.
[10] J. Hollingsworth,et al. Prostatic fibrosis is associated with lower urinary tract symptoms. , 2012, The Journal of urology.
[11] T. Tammela,et al. [Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe]. , 2012, Urologiia.
[12] Toshimitsu Kobayashi,et al. New classification for men with lower urinary tract symptoms: cluster analysis using the International Prostate Symptom Score , 2012, BJU international.
[13] T. Wilt,et al. Serenoa repens monotherapy for benign prostatic hyperplasia (BPH): an updated Cochrane systematic review , 2012, BJU international.
[14] B. Challacombe,et al. Is there a link between BPH and prostate cancer? , 2012, The Practitioner.
[15] G. Skipka,et al. Systematic review of surgical treatments for benign prostatic hyperplasia and presentation of an approach to investigate therapeutic equivalence (non‐inferiority) , 2012, BJU international.
[16] C. Roehrborn,et al. Effect of increasing doses of saw palmetto extract on lower urinary tract symptoms: a randomized trial. , 2011, JAMA.
[17] T. Tammela,et al. Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: the Enlarged Prostate International Comparator Study (EPICS) , 2011, BJU international.
[18] Thomas A. Wynn,et al. Integrating mechanisms of pulmonary fibrosis , 2011, The Journal of experimental medicine.
[19] C. Roehrborn,et al. Safety and feasibility of the prostatic urethral lift: a novel, minimally invasive treatment for lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH) , 2011, BJU international.
[20] John T. Wei,et al. Urologist compliance with AUA best practice guidelines for benign prostatic hyperplasia in Medicare population. , 2011, Urology.
[21] C. Roehrborn,et al. Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: Pathophysiology and mechanism(s) of action , 2011, Neurourology and urodynamics.
[22] O. Ogawa,et al. Efficacy of nondrug lifestyle measures for the treatment of nocturia. , 2010, The Journal of urology.
[23] A. Vannacci,et al. Acute liver damage due to Serenoa repens: a case report. , 2010, British journal of clinical pharmacology.
[24] D. Tindall,et al. Effect of dutasteride on the risk of prostate cancer. , 2010, The New England journal of medicine.
[25] I. Pearce,et al. Transurethral resection of the prostate syndrome: almost gone but not forgotten. , 2009, Journal of endourology.
[26] John T. Wei,et al. Differences in initial benign prostatic hyperplasia management between primary care physicians and urologists. , 2009, The Journal of urology.
[27] Andrea Tubaro,et al. The prevalence of lower urinary tract symptoms (LUTS) in the USA, the UK and Sweden: results from the Epidemiology of LUTS (EpiLUTS) study , 2009, BJU international.
[28] J. K. Parsons,et al. Lower urinary tract symptoms increase the risk of falls in older men , 2009, BJU international.
[29] M. Irigoyen,et al. A Brief Review of Chronic Exercise Intervention to Prevent Autonomic Nervous System Changes During the Aging Process , 2009, Clinics.
[30] P. Barnes,et al. Complementary and alternative medicine use among adults and children: United States, 2007. , 2008, National health statistics reports.
[31] O. Baylis,et al. Alpha antagonists and intraoperative floppy iris syndrome: A spectrum , 2008, Clinical ophthalmology.
[32] A. Grant,et al. Minimally invasive treatments for benign prostatic enlargement: systematic review of randomised controlled trials , 2008, BMJ : British Medical Journal.
[33] M. Melekos,et al. Is botulinum neurotoxin type A (BoNT-A) a novel therapy for lower urinary tract symptoms due to benign prostatic enlargement? A review of the literature. , 2008, European urology.
[34] M. Moyad,et al. Educating patients about lifestyle modifications for prostate health. , 2008, The American journal of medicine.
[35] Timothy J Wilt,et al. Practice patterns in benign prostatic hyperplasia surgical therapy: the dramatic increase in minimally invasive technologies. , 2008, The Journal of urology.
[36] S. Masket,et al. Clinical experience with intraoperative floppy‐iris syndrome: Results of the 2008 ASCRS member survey , 2008, Journal of cataract and refractive surgery.
[37] D. Dubey,et al. Thulium laser versus standard transurethral resection of the prostate: A randomized prospective trial , 2008, Indian journal of urology : IJU : journal of the Urological Society of India.
[38] Alexander Bachmann,et al. Morbidity, mortality and early outcome of transurethral resection of the prostate: a prospective multicenter evaluation of 10,654 patients. , 2008, The Journal of urology.
[39] T. Fenter,et al. Dutasteride vs finasteride: assessment of differences in acute urinary retention rates and surgical risk outcomes in an elderly population aged > or =65 years. , 2008, The American journal of managed care.
[40] H. Bream-Rouwenhorst,et al. Intraoperative Floppy Iris Syndrome Associated with α1-Adrenergic Receptor Antagonists , 2008, The Annals of pharmacotherapy.
[41] B. Schurch,et al. Botulinum toxin A (Botox) intradetrusor injections in adults with neurogenic detrusor overactivity/neurogenic overactive bladder: a systematic literature review. , 2008, European urology.
[42] M. Kattan,et al. Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. , 2007, Journal of the National Cancer Institute.
[43] C. Roehrborn. Self management for men with lower urinary tract symptoms: randomised controlled trial , 2007, BMJ : British Medical Journal.
[44] C. Roehrborn,et al. Combination therapy with doxazosin and finasteride for benign prostatic hyperplasia in patients with lower urinary tract symptoms and a baseline total prostate volume of 25 ml or greater. , 2006, The Journal of urology.
[45] C. Roehrborn,et al. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. , 2006, JAMA.
[46] R. Packard,et al. Intraoperative floppy-iris syndrome associated with tamsulosin. , 2006, Journal of cataract and refractive surgery.
[47] C. Chapple,et al. Botulinum toxin injections for neurogenic and idiopathic detrusor overactivity: A critical analysis of results. , 2006, European urology.
[48] P. Abrams,et al. Noninvasive methods of diagnosing bladder outlet obstruction in men. Part 1: Nonurodynamic approach. , 2006, The Journal of urology.
[49] L. Ferrucci,et al. Metabolic factors associated with benign prostatic hyperplasia. , 2006, The Journal of clinical endocrinology and metabolism.
[50] C. Bouza,et al. Systematic review and meta-analysis of Transurethral Needle Ablation in symptomatic Benign Prostatic Hyperplasia , 2006, BMC urology.
[51] I. Jibrin,et al. Saw palmetto-induced pancreatitis. , 2006, Southern medical journal.
[52] M. Chancellor,et al. Intraprostatic injection of botulinum toxin type- A relieves bladder outlet obstruction in human and induces prostate apoptosis in dogs , 2006, BMC urology.
[53] C. Roehrborn,et al. A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder. , 2006, European urology.
[54] L. Vatten,et al. The prevalence and correlates of urinary tract symptoms in Norwegian men: The HUNT Study , 2005, BJU international.
[55] R. Rosen,et al. Sexual dysfunction and lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). , 2005, European urology.
[56] John T. Wei,et al. Urologic diseases in America project: benign prostatic hyperplasia. , 2005, The Journal of urology.
[57] M. Elhilali,et al. Alfuzosin 10 mg once daily improves sexual function in men with lower urinary tract symptoms and concomitant sexual dysfunction , 2005, BJU international.
[58] N. Fried,et al. High-power thulium fiber laser ablation of urinary tissues at 1.94 microm. , 2005, Journal of endourology.
[59] T. Wilt,et al. Doxazosin for treating lower urinary tract symptoms compatible with benign prostatic obstruction: a systematic review of efficacy and adverse effects , 2004, BJU international.
[60] C. Roehrborn,et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. , 2003, The New England journal of medicine.
[61] M. Wyllie,et al. Safety and efficacy of alfuzosin 10 mg once‐daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double‐blind, placebo‐controlled studies , 2003, BJU international.
[62] A. Bentivoglio,et al. Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: results of a randomized, placebo-controlled study. , 2003, Urology.
[63] Michael M Lieber,et al. The influence of finasteride on the development of prostate cancer. , 2003, The New England journal of medicine.
[64] P. Boyle,et al. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. , 2002, Urology.
[65] Jie Deng,et al. Body size and serum levels of insulin and leptin in relation to the risk of benign prostatic hyperplasia. , 2002, The Journal of urology.
[66] M. Barry,et al. Risk factors for clinical benign prostatic hyperplasia in a community-based population of healthy aging men. , 2001, Journal of clinical epidemiology.
[67] B. Högstedt,et al. Hyperinsulinaemia as a Risk Factor for Developing Benign Prostatic Hyperplasia , 2001, European Urology.
[68] G. Bales,et al. Phytotherapeutic agents in the treatment of lower urinary tract symptoms: a demographic analysis of awareness and use at the University of Chicago. , 1999, Urology.
[69] T. Wilt,et al. Saw palmetto extracts for treatment of benign prostatic hyperplasia: a systematic review. , 1998, JAMA.
[70] A. Tewari,et al. A second phase III multicenter placebo controlled study of 2 dosages of modified release tamsulosin in patients with symptoms of benign prostatic hyperplasia. United States 93-01 Study Group. , 1998, The Journal of urology.
[71] R. Schmidt,et al. Botox‐induced prostatic involution , 1998, The Prostate.
[72] D M Barrett,et al. High-power potassium titanyl phosphate laser vaporization prostatectomy. , 1998, Mayo Clinic proceedings.
[73] C. Roehrborn,et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. , 1998, The New England journal of medicine.
[74] H. Lepor. Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Tamsulosin Investigator Group. , 1998, Urology.
[75] R C Bruskewitz,et al. Recent developments in the surgical management of benign prostatic hyperplasia. , 1998, Urology.
[76] P. Gilling,et al. The results of holmium laser resection of the prostate. , 1998, British journal of urology.
[77] P. Gilling,et al. The use of the holmium laser in the treatment of benign prostatic hyperplasia. , 1996, Journal of endourology.
[78] H. Lepor,et al. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. , 1996, The New England journal of medicine.
[79] M. Barry,et al. Benign prostatic hyperplasia specific health status measures in clinical research: how much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients? , 1995, The Journal of urology.
[80] W. Hop,et al. Natural history of benign prostatic hyperplasia: appropriate case definition and estimation of its prevalence in the community. , 1995, Urology.
[81] C. Fowler,et al. A multicenter, randomized, prospective study of endoscopic laser ablation versus transurethral resection of the prostate. , 1995, Urology.
[82] J. Kabalin,et al. A prospective randomized comparison of transurethral resection to visual laser ablation of the prostate for the treatment of benign prostatic hyperplasia. , 1995, Urology.
[83] D. Gillatt,et al. What is the 'normal range' for prostate-specific antigen? Use of a receiver operating characteristic curve to evaluate a serum marker. , 1995, British journal of urology.
[84] E. Rimm,et al. Obesity and benign prostatic hyperplasia. , 1994, American journal of epidemiology.
[85] F. Montorsi,et al. A modified prostatic UroLume Wallstent for healthy patients with symptomatic benign prostatic hyperplasia: a European Multicenter Study. , 1994, Urology.
[86] D. Peehl,et al. The IGF axis in the prostate. , 1994, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.
[87] C. C. Chen,et al. Natural history of prostatism: urinary flow rates in a community-based study. , 1993, The Journal of urology.
[88] C G Chute,et al. Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. , 1993, JAMA.
[89] J. Oesterling,et al. The prevalence of prostatism: a population-based survey of urinary symptoms. , 1993, The Journal of urology.
[90] M. Barry,et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. , 1992, The Journal of urology.
[91] E. Shapiro. Embryologic development of the prostate. Insights into the etiology and treatment of benign prostatic hyperplasia. , 1990, The Urologic clinics of North America.
[92] C. West,et al. Maximum and average urine flow rates in normal male and female populations--the Liverpool nomograms. , 1989, British journal of urology.
[93] K. Kurth,et al. Benign prostatic hyperplasia treated by castration or the LH-RH analogue buserelin: a report on 6 cases. , 1987, European urology.
[94] P. Walsh,et al. The development of human benign prostatic hyperplasia with age. , 1984, The Journal of urology.
[95] S. Meretyk,et al. A placebo-controlled double-blind study of the effect of phenoxybenzamine in benign prostatic obstruction. , 1978, British journal of urology.
[96] S. Raz,et al. Adrenergic and cholinergic receptors in the human prostate, prostatic capsule and bladder neck. , 1975, British journal of urology.
[97] J. W. White. I. The Question of Castration for Enlarged Prostate. , 1896, Annals of surgery.
[98] A. T. Cabot. II. The Question of Castration for Enlarged Prostate. , 1896, Annals of surgery.
[99] C. Roehrborn,et al. A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with alpha-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia , 2012 .
[100] M. Emberton,et al. Guidelines on the Treatment of Non-neurogenic Male LUTS , 2011 .
[101] G. Vannelli,et al. Characterization of phosphodiesterase type 5 expression and functional activity in the human male lower urinary tract. , 2010, The journal of sexual medicine.
[102] C. Roehrborn,et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. , 2010, European urology.
[103] H. Lepor,et al. The QT Interval and Selection of Alpha-Blockers for Benign Prostatic Hyperplasia. , 2008, Reviews in urology.
[104] T. Wilt,et al. Microwave thermotherapy for benign prostatic hyperplasia. , 2007, The Cochrane database of systematic reviews.
[105] J. Dimitrakov. Saw palmetto for benign prostatic hyperplasia. , 2006, The New England journal of medicine.
[106] V. Nitti. Pressure flow urodynamic studies: the gold standard for diagnosing bladder outlet obstruction. , 2005, Reviews in urology.
[107] M. Pinzani. Liver fibrosis , 2004, Springer Seminars in Immunopathology.
[108] P. Boyle,et al. Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial. , 2003, Urology.
[109] S. Kaplan. Terazosin for treating symptomatic benign prostatic obstruction: a systematic review of efficacy and adverse effects. , 2002, The Journal of urology.
[110] T. Wilt,et al. Tamsulosin for treating lower urinary tract symptoms compatible with benign prostatic obstruction: a systematic review of efficacy and adverse effects. , 2002, The Journal of urology.
[111] D. Porru,et al. Evaluation of morbidity of multi‐channel pressure‐flow studies , 1999, Neurourology and urodynamics.
[112] P. Abrams. LUTS, BPH, BPE, BPO: A Plea for the Logical Use of Correct Terms. , 1999, Reviews in urology.
[113] C C Schulman,et al. Transurethral needle ablation (TUNA): safety, feasibility, and tolerance of a new office procedure for treatment of benign prostatic hyperplasia. , 1993, European urology.
[114] P. Walsh,et al. Clinical and experimental studies of benign prostatic hyperplasia. , 1990, The Urologic clinics of North America.
[115] D. S. Coffey,et al. Etiology and disease process of benign prostatic hyperplasia , 1989, The Prostate. Supplement.
[116] K. Fabian. [The intra-prostatic "partial catheter" (urological spiral) (author's transl)]. , 1980, Der Urologe. Ausg. A.